Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

ipharma Tirzpsema 34mg/pen

R 2,550.00
Add to WishlistCompare

iPharma Tirzepsema 34 mg — Pre-Filled Pen

Metabolic Research | GLP-1 & GIP Signaling | Appetite Regulation

Product Overview

iPharma Tirzepsema 34 mg is a pre-filled pen-format product marketed as a combination of tirzepatide and semaglutide, with a labelled total strength of 34 mg.

Tirzepatide acts on two metabolic hormone receptors, GIP and GLP-1, while semaglutide acts on the GLP-1 receptor. These pathways are involved in appetite signaling, blood-glucose regulation and energy balance.

Both compounds have been studied extensively in clinical research, particularly in relation to type 2 diabetes and weight management.

Key Research Findings

1. Body-Weight Reduction

In the 72-week SURMOUNT-1 clinical trial, participants receiving tirzepatide experienced average body-weight reductions of 15.0%, 19.5% and 20.9% across the three studied dose groups.

These results were obtained using specified tirzepatide treatment regimens in adults with obesity or overweight and weight-related complications, excluding diabetes. They cannot be used to predict results from this combination product.

2. Appetite Regulation

Semaglutide and tirzepatide influence incretin-related signaling pathways involved in appetite and food intake. Clinical studies of their authorized formulations have demonstrated effects on body weight, but outcomes vary by treatment, population and individual factors.

3. Blood-Glucose Regulation

Both compounds have demonstrated improvements in blood-glucose control in clinical trials involving people with type 2 diabetes. These findings apply to the specific medicinal formulations and treatment protocols studied, not automatically to an unverified combination pen.

4. Metabolic Health Research

Clinical trials of tirzepatide and semaglutide have examined body weight and several cardiometabolic markers. However, evidence from separate trials does not establish that combining both compounds improves outcomes or produces a favorable overall benefit-risk profile.

Key Features
  • Pre-filled multi-dose pen format for research convenience
  • Sterile, single-use disposable needles included (x10)
  • Dual receptor-pathway compound blend
  • For laboratory/research use only — not for human or veterinary use
Dosage & Usage

Tirzepsema is intended for use exclusively within controlled laboratory research settings. Potential research contexts include:

  • In vitro and in vivo studies examining GLP-1 and GIP receptor pathway activity
  • Comparative studies on incretin-mimetic compound behavior
  • Metabolic and endocrine pathway research
  • Peptide stability and formulation studies

This product is supplied strictly for use by qualified researchers in appropriately licensed laboratory environments. It is not intended for diagnostic, therapeutic, or human/veterinary use of any kind.

Handling & Storage

  • Store refrigerated at 2–8°C (36–46°F). Do not freeze.
  • Protect from light; keep in original packaging until use.
  • Once in use, follow standard cold-chain handling practices for peptide stability.
  • Inspect visually prior to use — do not use if solution is discolored or contains particulate matter.
  • Keep out of reach of children and unauthorized personnel.
  • Dispose of used needles in an approved sharps container in accordance with local laboratory waste regulations.

FAQ's & Tips

Q: What is Tirzepsema?
A: A research-grade combination peptide formulation containing Tirzepatide and Semaglutide, intended strictly for laboratory research purposes.

Q: Is this approved for clinical or personal use?
A: No. This product is sold exclusively for research purposes and is not approved for human consumption, clinical use, or veterinary application.

Q: Is the combination of these two peptides independently studied?
A: Each compound has its own body of research individually. Research specifically evaluating their co-administration as a combined formulation is limited/not established in current published literature.

Research

Research Overview
Tirzepatide and Semaglutide are both well-characterized incretin-mimetic compounds independently studied for their effects on glucose metabolism and appetite regulation via GLP-1 receptor pathways, with Tirzepatide additionally acting on the GIP receptor. [I'd note here rather than skip past it: research specifically on the combined co-administration of these two peptides together is not established in published literature — the individual mechanisms don't necessarily predict outcomes when combined, and I'd flag that clearly rather than imply otherwise in the copy.]

Product Features

  • Pre-filled multi-dose pen format for research convenience
  • Sterile, single-use disposable needles included (x10)
  • Dual receptor-pathway compound blend
Reviews